Why Wave Life Sciences, Inc.’s (WVE) Stock Is Down 5.03%
As of Wednesday, September 02, Wave Life Sciences, Inc.’s WVE share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington’s disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Wave Life Sciences Ltd.’s (WVE) Stock Is Up 5.35%
As of Wednesday, August 12, Wave Life Sciences Ltd.’s WVE share price has surged by 5.35%, which has investors questioning if this is right time to sell.Michael Rose
Is Wave Life Sciences Ltd. (WVE) Overvalued?
We dive into why Wave Life Sciences Ltd. (WVE) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Rosalio Madrigal
What You Need to Know About Wave Life Sciences Ltd.'s Q3 Earnings
Wave Life Sciences Ltd.'s fiscal Q3 earnings report was released on Thursday, July 30. Let's dive in to see if (WVE) missed or beat analyst's expectations.Michael Rose
Why Wave Life Sciences Ltd.’s (WVE) Stock Is Down 5.39%
As of Friday, July 10, Wave Life Sciences Ltd.’s WVE share price has dipped by 5.39%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | WVE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $961.6 | $674.0 | 44% |
|
| Shares Out (Mil) | 204.0 | 43.9 | 77% |
|
| Institutional Ownership | 99.4% | 84.7% | 88% |
|
| Float (Mil) | 94.6 | 47.3 | 60% |
|
| Beta | -1.29 | 0.71 | 1% |
|
| Avg Daily Volume (000s) | 3,193 | 293 | 89% |
|
| Price Change (52-week) |
(49.3%) | 68.8% | 15% |
|
| Growth | WVE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 16.3% | 6.8% | 75% |
|
| Net Income (5yr) | (6.4%) | (1.5%) | 32% |
|
| EPS (5yr) | 20.5% | 14.9% | 69 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 13.4% | (15.1%) | 71% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 12 | 13 | |
| Current EPS | ($0.317) | ($1.109) | ($1.191) | |
| Month Ago EPS | ($0.323) | ($1.131) | ($1.162) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 2 | 0 | 1 | |
| Three Months Ago EPS | ($0.315) | ($0.875) | ($1.108) | |
| Year/Year Chg | (6.8%) | (8.5%) | (0.5%) | |
| Financials | WVE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $65 | $317 | 22% |
|
| Net Income (TTM) (Mil) | ($203) | ($11) | 7% |
|
| EPS (TTM) | ($1.077) | ($0.700) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($192) | ($7) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $160 | $4 | 82% |
|
| Long-Term Debt (Q1) (Mil) | $40 | $6 | 37% |
|
| Enterprise Value (Q1) (Mil) | $642 | $575 | 36% |
|
| Valuation | WVE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.08 | 2.80 | 51% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | WVE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (202.0%) | 67.5% | 1% |
|
| Net Margin | (309.7%) | (1.4%) | 3% |
|
| ROA | (50.0%) | (24.6%) | 12% |
|
| ROE | (68.3%) | (21.4%) | 12% |
|
| Liabilities to Assets | 18.8% | 32.2% | 12% |
|
| F-Score | 3 | 3 | 18% |
|
Wave Life Sciences, Inc. did not pass any screens on 9/2/2026.
